Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Joke M. M. den Haan is active.

Publication


Featured researches published by Joke M. M. den Haan.


Proceedings of the National Academy of Sciences of the United States of America | 2010

Effective collaboration between marginal metallophilic macrophages and CD8+ dendritic cells in the generation of cytotoxic T cells

Ronald Backer; Timo Schwandt; Mascha Greuter; Marije Oosting; Frank Jüngerkes; Thomas Tüting; Louis Boon; Tom O’Toole; Georg Kraal; Andreas Limmer; Joke M. M. den Haan

The spleen is the lymphoid organ that induces immune responses toward blood-borne pathogens. Specialized macrophages in the splenic marginal zone are strategically positioned to phagocytose pathogens and cell debris, but are not known to play a role in the activation of T-cell responses. Here we demonstrate that splenic marginal metallophilic macrophages (MMM) are essential for cross-presentation of blood-borne antigens by splenic dendritic cells (DCs). Our data demonstrate that antigens targeted to MMM as well as blood-borne adenoviruses are efficiently captured by MMM and exclusively transferred to splenic CD8+ DCs for cross-presentation and for the activation of cytotoxic T lymphocytes. Depletion of macrophages in the marginal zone prevents cytotoxic T-lymphocyte activation by CD8+ DCs after antibody targeting or adenovirus infection. Moreover, we show that tumor antigen targeting to MMM is very effective as antitumor immunotherapy. Our studies point to an important role for splenic MMM in the initial steps of CD8+ T-cell immunity by capturing and concentrating blood-borne antigens and the transfer to cross-presenting DCs which can be used to design vaccination strategies to induce antitumor cytotoxic T-cell immunity.


Molecular Immunology | 2009

Targeting glycan modified OVA to murine DC-SIGN transgenic dendritic cells enhances MHC class I and II presentation

Satwinder Kaur Singh; Johannes Stephani; Martin Schaefer; Hakan Kalay; Juan J. Garcia-Vallejo; Joke M. M. den Haan; Eirikur Saeland; Tim Sparwasser; Yvette van Kooyk

Dendritic cells have gained much interest in the field of anti-cancer vaccine development because of their central function in immune regulation. One of the receptors that facilitate DC-specific targeting of antigens is the DC-specific C-type lectin DC-SIGN. Although DC-SIGN is specifically expressed on human DCs, its murine homologue is not present on any murine DC subsets, which makes in vivo evaluation of potential DC-SIGN targeting vaccines very difficult. Here we describe the use of DC-SIGN transgenic mice, as a good model system to evaluate DC-SIGN targeting vaccines. We demonstrate that glycan modification of OVA with DC-SIGN targeting glycans, targets antigen specifically to bone marrow (BM)** derived DCs and splenic DCs. Glycan modification of OVA with Lewis X or Lewis B oligosaccharides, that target DC-SIGN transgenic DCs, resulted in efficient 10-fold induction of OT-II compared to unmodified OVA. Interestingly, glycan modified OVA proteins were significantly cross-presented to OT-I T cells by wild type DC, 10-fold more than native OVA, and the expression of DC-SIGN further enhanced this cross-presentation. Targeting of glycosylated OVA was neither accompanied with any DC maturation, nor the production of inflammatory or anti-inflammatory cytokines. Thus, we conclude that glycan modification of antigens and targeting to DC-SIGN enhance both CD4 and CD8 T cell responses. Furthermore, our data demonstrate that DC-SIGN transgenic mice are valuable tool for optimisation and efficiency testing of DC vaccination strategies that are designed to target in particular the human DC-SIGN receptor.


PLOS ONE | 2009

P-Glycoprotein Acts as an Immunomodulator during Neuroinflammation

Gijs Kooij; Ronald Backer; Jasper J. Koning; Arie Reijerkerk; Jack van Horssen; Susanne M. A. van der Pol; Joost A. R. Drexhage; Alfred H. Schinkel; Christine D. Dijkstra; Joke M. M. den Haan; Teunis B. H. Geijtenbeek; Helga E. de Vries

Background Multiple sclerosis is an inflammatory demyelinating disease of the central nervous system in which autoreactive myelin-specific T cells cause extensive tissue damage, resulting in neurological deficits. In the disease process, T cells are primed in the periphery by antigen presenting dendritic cells (DCs). DCs are considered to be crucial regulators of specific immune responses and molecules or proteins that regulate DC function are therefore under extensive investigation. We here investigated the potential immunomodulatory capacity of the ATP binding cassette transporter P-glycoprotein (P-gp). P-gp generally drives cellular efflux of a variety of compounds and is thought to be involved in excretion of inflammatory agents from immune cells, like DCs. So far, the immunomodulatory role of these ABC transporters is unknown. Methods and Findings Here we demonstrate that P-gp acts as a key modulator of adaptive immunity during an in vivo model for neuroinflammation. The function of the DC is severely impaired in P-gp knockout mice (Mdr1a/1b−/−), since both DC maturation and T cell stimulatory capacity is significantly decreased. Consequently, Mdr1a/1b −/− mice develop decreased clinical signs of experimental autoimmune encephalomyelitis (EAE), an animal model for multiple sclerosis. Reduced clinical signs coincided with impaired T cell responses and T cell-specific brain inflammation. We here describe the underlying molecular mechanism and demonstrate that P-gp is crucial for the secretion of pro-inflammatory cytokines such as TNF-α and IFN-γ. Importantly, the defect in DC function can be restored by exogenous addition of these cytokines. Conclusions Our data demonstrate that P-gp downmodulates DC function through the regulation of pro-inflammatory cytokine secretion, resulting in an impaired immune response. Taken together, our work highlights a new physiological role for P-gp as an immunomodulatory molecule and reveals a possible new target for immunotherapy.


European Journal of Immunology | 2008

CD8– dendritic cells preferentially cross-present Saccharomyces cerevisiae antigens

Ronald Backer; Fred W. van Leeuwen; Georg Kraal; Joke M. M. den Haan

Mouse splenic dendritic cell (DC) subsets possess distinct antigen‐presentation abilities. CD8+ DC are specialized in cross‐presentation of antigens to CD8+ T cells, whereas CD8– DC are more efficient in antigen presentation to CD4+ T cells. In this study, we examined the capacity of CD8+ and CD8– DC subsets to present fungal antigens in MHC class I and II molecules to CD8+ and CD4+ T cells, respectively. We used ovalbumin‐expressing Saccharomyces cerevisiae (yeast‐OVA) as a fungal model system. Both CD8+ and CD8– DC subsets phagocytosed yeast in equal amounts and uptake was mediated via dectin‐1. In addition, both DC subsets induced similar OVA‐specific CD4+ T cell proliferation after incubation with yeast‐OVA. However, the induction of OVA‐specific CD8+ T cell activation was largely restricted to the CD8– DC subset. Furthermore, only CD8– DC produced cytokines such as IL‐10 and TNF‐α and increased IL‐23p19 and IL‐23p40 mRNA levels in response to yeast. Our results strongly suggest that DC subsets have different functions in the elicitation of adaptive immune responses in vivo.


Frontiers in Immunology | 2012

Stromal cells of the mouse spleen.

Joke M. M. den Haan; Reina E. Mebius; Georg Kraal

The composition and function of stromal cells in the white pulp of the spleen resemble to a large extent the situation in other secondary lymphoid organs such as lymph nodes. The stromal cells play an important role in the support and guidance of lymphocytes and myeloid cells in the T and B cell zones of the spleen. Major differences of the spleen are found in the way cells enter the white pulp and the composition of stromal cells in the red pulp. In this review, the features of stromal cells of both white and red pulp will be described in light of the function of the spleen.


Immunology Letters | 2014

The activation of the adaptive immune system: Cross-talk between antigen-presenting cells, T cells and B cells

Joke M. M. den Haan; Ramon Arens; Menno C. van Zelm

The adaptive immune system consists of T and B cells that express clonally distributed antigen receptors. To achieve functional adaptive immune responses, antigen-specific T cell populations are stimulated by professional antigen-presenting cells like dendritic cells (DCs), which provide crucial stimulatory signals for efficient expansion and development of effector functions. Antigen-specific B cells receive costimulatory signals from helper T cells to stimulate affinity maturation and isotype switching. Here we elaborate on the interactions between DCs, T cells and B cells, and on the important signals for efficient induction of adaptive immune responses.


Molecular Immunology | 2012

Nod2 improves barrier function of intestinal epithelial cells via enhancement of TLR responses

Ida H. Hiemstra; Gerd Bouma; Dirk Geerts; Georg Kraal; Joke M. M. den Haan

Intestinal epithelial cells (IECs) form a physical barrier between the internal milieu and the intestinal microflora via the expression of tight junctions. TLR-mediated recognition of intestinal microflora by IECs is important for tight junction preservation, production of chemokines, and cell survival. Disturbance of the IEC barrier function results in bacterial invasion and contributes to the development of inflammatory bowel disease. We observed that muramyl dipeptide (MDP), a breakdown product of bacterial peptidoglycan, strongly enhances subsequent Toll-like receptor (TLR) responses in murine colonic epithelium cell lines. Prior exposure to MDP significantly increased the production of chemokines and cytokines and improved the barrier function induced by different TLR2 and TLR4 ligands. shRNA knock-down studies showed that MDP recognition by Nod2 mediated the enhancement of TLR responses. Our studies indicate that Nod2 stimulation by MDP significantly enhances TLR-mediated IEC barrier function and chemokine production. Failure of this protective mechanism may contribute to the increased risk of Crohns disease in individuals with a loss-of-function mutation in NOD2.


Proceedings of the National Academy of Sciences of the United States of America | 2016

Sialic acid-modified antigens impose tolerance via inhibition of T-cell proliferation and de novo induction of regulatory T cells

Maurizio Perdicchio; Juan M. Ilarregui; Marleen I. Verstege; Lenneke A. M. Cornelissen; Sjoerd T. T. Schetters; Steef Engels; Martino Ambrosini; Hakan Kalay; Henrike Veninga; Joke M. M. den Haan; Lisette A. van Berkel; Janneke N. Samsom; Paul R. Crocker; Tim Sparwasser; Luciana Berod; Juan J. Garcia-Vallejo; Yvette van Kooyk; Wendy W. J. Unger

Significance Sialic acids are terminal glycan structures present on cellular glycoproteins and often overexpressed on certain pathogens and tumors. Sialic acids interact with sialic acid-binding Ig-type lectin (siglec) receptors, suggesting a potential regulatory role in homeostasis or pathology-mediated immune modulation. Here, we show that modification of antigens with sialic acids alters their immunogenicity. Sialylated antigens impose a regulatory program on dendritic cells (DCs) via Siglec-E. DCs loaded with sialylated antigens induce de novo regulatory T (Treg) cells and inhibit the generation of new effector T cells as well as the function of existing ones. This dual tolerogenic DC function is maintained under inflammatory conditions and, therefore, sialylation of antigens could provide a novel way to induce antigen-specific immune tolerance to treat patients who suffer from autoimmunity and allergies. Sialic acids are negatively charged nine-carbon carboxylated monosaccharides that often cap glycans on glycosylated proteins and lipids. Because of their strategic location at the cell surface, sialic acids contribute to interactions that are critical for immune homeostasis via interactions with sialic acid-binding Ig-type lectins (siglecs). In particular, these interactions may be of importance in cases where sialic acids may be overexpressed, such as on certain pathogens and tumors. We now demonstrate that modification of antigens with sialic acids (Sia-antigens) regulates the generation of antigen-specific regulatory T (Treg) cells via dendritic cells (DCs). Additionally, DCs that take up Sia-antigen prevent formation of effector CD4+ and CD8+ T cells. Importantly, the regulatory properties endowed on DCs upon Sia-antigen uptake are antigen-specific: only T cells responsive to the sialylated antigen become tolerized. In vivo, injection of Sia-antigen–loaded DCs increased de novo Treg-cell numbers and dampened effector T-cell expansion and IFN-γ production. The dual tolerogenic features that Sia-antigen imposed on DCs are Siglec-E–mediated and maintained under inflammatory conditions. Moreover, loading DCs with Sia-antigens not only inhibited the function of in vitro–established Th1 and Th17 effector T cells but also significantly dampened ex vivo myelin-reactive T cells, present in the circulation of mice with experimental autoimmune encephalomyelitis. These data indicate that sialic acid-modified antigens instruct DCs in an antigen-specific tolerogenic programming, enhancing Treg cells and reducing the generation and propagation of inflammatory T cells. Our data suggest that sialylation of antigens provides an attractive way to induce antigen-specific immune tolerance.


European Journal of Immunology | 2015

Antigen targeting reveals splenic CD169+macrophages as promoters of germinal center B-cell responses

Henrike Veninga; Ellen G.F. Borg; Kyle Vreeman; Philip R. Taylor; Hakan Kalay; Yvette van Kooyk; Georg Kraal; Luisa Martinez-Pomares; Joke M. M. den Haan

Ag delivery to specific APCs is an attractive approach in developing strategies for vaccination. CD169+ macrophages in the marginal zone of the spleen represent a suitable target for delivery of Ag because of their strategic location, which is optimal for the capture of blood‐borne Ag and their close proximity to B cells and T cells in the white pulp. Here we show that Ag targeting to CD169+ macrophages in mice resulted in strong, isotype‐switched, high‐affinity Ab production and the preferential induction and long‐term persistence of Ag‐specific GC B cells and follicular Th cells. In agreement with these observations, CD169+ macrophages retained intact Ag, induced cognate activation of B cells, and increased expression of costimulatory molecules upon activation. In addition, macrophages were required for the production of cytokines that promote B‐cell responses. Our results identify CD169+ macrophages as promoters of high‐affinity humoral immune responses and emphasize the value of CD169 as target for Ag delivery to improve vaccine responses.


Vaccine | 2011

Delivery route, MyD88 signaling and cross-priming events determine the anti-tumor efficacy of an Adenovirus based melanoma vaccine

Basav N. Hangalapura; Dinja Oosterhoff; Tarun Gupta; Jan de Groot; Pepijn G.J.T.B. Wijnands; Victor W. van Beusechem; Joke M. M. den Haan; Thomas Tüting; Alfons J.M. van den Eertwegh; David T. Curiel; Rik J. Scheper; Tanja D. de Gruijl

Adenovirus (Ad)-based vaccines are considered for cancer immunotherapy, yet, detailed knowledge on their mechanism of action and optimal delivery route for anti-tumor efficacy is lacking. Here, we compared the anti-tumor efficacy of an Ad-based melanoma vaccine after intradermal, intravenous, intranasal or intraperitoneal delivery in the B16F10 melanoma model. The intradermal route induced superior systemic anti-melanoma immunity which was MyD88 signaling-dependent. Predominant transduction of non-professional antigen-presenting cells at the dermal vaccination sites and draining lymph nodes, suggested a role for cross-presentation, which was confirmed in vitro. We conclude that the dermis provides an optimal route of entry for Ad-based vaccines for high-efficacy systemic anti-tumor immunization and that this immunization likely involves cross-priming events in the draining lymph nodes.

Collaboration


Dive into the Joke M. M. den Haan's collaboration.

Top Co-Authors

Avatar

Georg Kraal

VU University Medical Center

View shared research outputs
Top Co-Authors

Avatar

Henrike Veninga

VU University Medical Center

View shared research outputs
Top Co-Authors

Avatar

Yvette van Kooyk

VU University Medical Center

View shared research outputs
Top Co-Authors

Avatar

Hakan Kalay

VU University Medical Center

View shared research outputs
Top Co-Authors

Avatar

Ida H. Hiemstra

VU University Medical Center

View shared research outputs
Top Co-Authors

Avatar

Reina E. Mebius

VU University Medical Center

View shared research outputs
Top Co-Authors

Avatar

Ronald Backer

VU University Medical Center

View shared research outputs
Top Co-Authors

Avatar

Ellen G.F. Borg

VU University Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge